Showing results (111-120 of 153) with videos related to
Sort By:
Pageof 16
NPJ Breast Cancer|November 8, 2022
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancerCaner Mercan, Maschenka Balkenhol, Roberto Salgado, et al.Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.Cell Reports|April 6, 2022
FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancerSandra Tavares, Nalan Liv, Milena Pasolli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.Pageof 16